The global Bloodstream Infection Testing Market is expanding as the prevalence of sepsis, hospital-acquired infections, and antimicrobial-resistant infections continues to increase worldwide. Bloodstream infection testing plays an important role in identifying bacterial and fungal pathogens and supporting timely treatment decisions. Hospitals, diagnostic laboratories, and critical care units are increasingly adopting automated blood culture systems, PCR-based diagnostics, multiplex testing platforms, and advanced molecular technologies to improve pathogen detection and reduce diagnostic turnaround time.

According to Fortune Business Insights, the global Bloodstream Infection Testing Market was valued at USD 800.98 million in 2025 and is projected to grow from USD 837.61 million in 2026 to USD 1,197.82 million by 2034, exhibiting a CAGR of 4.57% during the forecast period.

Why is the Bloodstream Infection Testing Market Growing?

The increasing incidence of sepsis and healthcare-associated infections is a major factor driving demand for bloodstream infection testing. Early identification of pathogens is important for selecting appropriate antimicrobial treatment and supporting infection-control measures. Hospitals are therefore increasing their adoption of automated blood culture systems and rapid molecular diagnostic platforms.

The growing emphasis on antimicrobial stewardship, rapid pathogen identification, hospital infection control, and critical-care diagnostics is further supporting market expansion. Advances in PCR, multiplex molecular diagnostics, automated microbiology, and AI-assisted pathogen analysis are creating new opportunities for faster and more efficient bloodstream infection testing.

Key Market Trends Shaping Industry Growth

Increasing Adoption of Rapid Molecular Diagnostics

Hospitals are increasingly adopting rapid molecular diagnostic technologies capable of identifying bloodstream pathogens in a shorter time than conventional testing workflows. PCR-based systems and multiplex panels are gaining importance in intensive care units and emergency departments.

Growing Use of Automated Blood Culture Systems

Automated blood culture instruments are becoming increasingly important for continuous microbial monitoring and faster detection of bloodstream infections. Automation can improve laboratory workflow efficiency and reduce manual intervention.

Increasing Focus on Antimicrobial Stewardship

Healthcare providers are placing greater emphasis on antimicrobial stewardship programs to reduce inappropriate antibiotic use. Rapid identification of pathogens and resistance markers can support more targeted treatment decisions.

Growing Adoption of Multiplex Testing

Multiplex diagnostic platforms can identify multiple pathogens and resistance markers through a single testing workflow. This is increasing their adoption in hospitals managing complex bloodstream infections.

Integration of AI and Digital Laboratory Technologies

AI-assisted microbial analytics, cloud-connected laboratory systems, automated sample preparation, and digital microbiology workflows are increasingly being incorporated into modern infection-testing platforms.

Market Dynamics

Driver: Rising Incidence of Sepsis and Hospital-Acquired Infections

The growing prevalence of sepsis and healthcare-associated infections is the primary driver of the Bloodstream Infection Testing Market. Bloodstream infections can require rapid pathogen identification to support timely clinical management.

Hospitals are increasingly implementing automated blood culture systems, PCR platforms, and multiplex diagnostic technologies to improve detection and support antimicrobial stewardship. The increasing awareness of early sepsis detection is also encouraging healthcare providers to strengthen infection-testing capabilities.